Aftab Dana, EVP of Research and Development at Exelixis, Inc. ($EXEL), sold $5.57 million in shares across four open market transactions in the past year, with his most recent sale on February 24, 2026. These EXEL insider sales rank 1,791st among 11,678 individuals in our database, trailing the average of $8.6 million per insider over 6.4 transactions. Dana recorded no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 26, 2026 | EXELIXIS, INC. | $EXEL | Aftab Dana | EVP, Research and Development | A | Common Stock | 52018 | $0.00 | 673,959.0000 | 281,863,000 | 8.36% | 0.02% |
| Feb. 24, 2026 | EXELIXIS, INC. | $EXEL | Aftab Dana | EVP, Research and Development | S | Common Stock | 47918 | $44.50 | 621,941.0000 | 281,863,000 | 7.15% | 0.02% |
| Feb. 19, 2026 | EXELIXIS, INC. | $EXEL | Aftab Dana | EVP, Research and Development | S | Common Stock | 29873 | $44.35 | 669,859.0000 | 281,863,000 | 4.27% | 0.01% |
| Feb. 15, 2026 | EXELIXIS, INC. | $EXEL | Aftab Dana | EVP, Research and Development | F | Common Stock | 26485 | $43.92 | 712,452.0000 | 281,863,000 | 3.58% | 0.01% |
| Feb. 15, 2026 | EXELIXIS, INC. | $EXEL | Aftab Dana | EVP, Research and Development | F | Common Stock | 12720 | $43.92 | 699,732.0000 | 281,863,000 | 1.79% | 0.00% |
| Jan. 15, 2026 | EXELIXIS, INC. | $EXEL | Aftab Dana | EVP, Research and Development | F | Common Stock | 27254 | $45.23 | 738,937.0000 | 281,863,000 | 3.56% | 0.01% |
| Jan. 15, 2026 | EXELIXIS, INC. | $EXEL | Aftab Dana | EVP, Research and Development | A | Common Stock | 119578 | $0.00 | 766,191.0000 | 281,863,000 | 18.49% | 0.04% |
| Nov. 21, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | EVP, Research and Development | G | Common Stock | 24000 | $0.00 | 646,613.0000 | 283,701,000 | 3.58% | 0.01% |
| Nov. 11, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | EVP, Research and Development | S | Common Stock | 48383 | $42.50 | 670,613.0000 | 283,701,000 | 6.73% | 0.02% |
| Oct. 8, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | EVP, Research & Development | A | Common Stock | 50673 | $0.00 | 718,996.0000 | 283,701,000 | 7.58% | 0.02% |
| May 15, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 30693 | $44.65 | 668,323.0000 | 296,132,000 | 4.39% | 0.01% |
| May 1, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | S | Common Stock | 1508 | $39.00 | 699,016.0000 | 296,132,000 | 0.22% | 0.00% |
| March 31, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | A | Common Stock | 132819 | $0.00 | 699,771.0000 | 296,132,000 | 23.43% | 0.04% |
| Feb. 26, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | A | Common Stock | 49209 | $0.00 | 566,952.0000 | 296,132,000 | 9.50% | 0.02% |
| Feb. 24, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | S | Common Stock | 26987 | $36.75 | 517,743.0000 | 296,132,000 | 4.95% | 0.01% |
| Feb. 15, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 12695 | $35.00 | 544,730.0000 | 296,132,000 | 2.28% | 0.00% |
| Feb. 15, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 16053 | $35.00 | 557,425.0000 | 296,132,000 | 2.80% | 0.01% |
| Jan. 16, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 22570 | $37.27 | 573,478.0000 | 296,132,000 | 3.79% | 0.01% |
| Jan. 16, 2025 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | A | Common Stock | 104106 | $0.00 | 596,048.0000 | 296,132,000 | 21.16% | 0.04% |
| Nov. 15, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 12838 | $35.05 | 491,942.0000 | 296,994,000 | 2.54% | 0.00% |
| Nov. 5, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | M | Common Stock | 96986 | $18.80 | 601,766.0000 | 296,994,000 | 19.21% | 0.03% |
| Nov. 5, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | S | Common Stock | 96986 | $35.00 | 504,780.0000 | 296,994,000 | 16.12% | 0.03% |
| Nov. 5, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | M | Option (right to buy) | 96986 | $0.00 | 0.0000 | 296,994,000 | 100.00% | 0.03% |
| Oct. 30, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | S | Common Stock | 1162 | $31.40 | 504,780.0000 | 296,994,000 | 0.23% | 0.00% |
| Aug. 12, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | S | Common Stock | 20883 | $27.06 | 505,942.0000 | 321,464,000 | 3.96% | 0.01% |
| Aug. 7, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | M | Option (right to buy) | 95000 | $0.00 | 0.0000 | 321,464,000 | 100.00% | 0.03% |
| Aug. 7, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | S | Common Stock | 95000 | $25.00 | 526,825.0000 | 321,464,000 | 15.28% | 0.03% |
| Aug. 7, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | M | Common Stock | 95000 | $24.41 | 621,825.0000 | 321,464,000 | 18.03% | 0.03% |
| May 15, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 7538 | $20.99 | 535,483.0000 | 321,464,000 | 1.39% | 0.00% |
| May 15, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 6409 | $20.99 | 543,021.0000 | 321,464,000 | 1.17% | 0.00% |
| May 15, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 8658 | $20.99 | 526,825.0000 | 321,464,000 | 1.62% | 0.00% |
| Feb. 23, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | A | Common Stock | 63350 | $0.00 | 548,216.0000 | 321,464,000 | 13.07% | 0.02% |
| Feb. 15, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 10630 | $20.39 | 484,866.0000 | 321,464,000 | 2.15% | 0.00% |
| Jan. 11, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | A | Common Stock | 63224 | $0.00 | 507,102.0000 | 321,464,000 | 14.24% | 0.02% |
| Jan. 11, 2024 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 11606 | $22.86 | 495,496.0000 | 321,464,000 | 2.29% | 0.00% |
| Sept. 6, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | A | Common Stock | 50660 | $0.00 | 456,438.0000 | 324,556,000 | 12.48% | 0.02% |
| Sept. 6, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 12560 | $22.27 | 443,878.0000 | 324,556,000 | 2.75% | 0.00% |
| Aug. 30, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | S | Common Stock | 4600 | $22.47 | 405,778.0000 | 324,556,000 | 1.12% | 0.00% |
| Aug. 15, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 6280 | $21.51 | 410,378.0000 | 324,556,000 | 1.51% | 0.00% |
| May 15, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 6115 | $19.18 | 416,658.0000 | 324,556,000 | 1.45% | 0.00% |
| May 15, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 4373 | $19.18 | 422,773.0000 | 324,556,000 | 1.02% | 0.00% |
| April 3, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | A | Common Stock | 68331 | $0.00 | 425,638.0000 | 324,556,000 | 19.12% | 0.02% |
| Feb. 27, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | M | Common Stock | 10 | $14.74 | 357,317.0000 | 324,556,000 | 0.00% | 0.00% |
| Feb. 27, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | S | Common Stock | 10 | $17.50 | 357,307.0000 | 324,556,000 | 0.00% | 0.00% |
| Feb. 28, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | S | Common Stock | 82490 | $17.50 | 357,307.0000 | 324,556,000 | 18.76% | 0.03% |
| Feb. 27, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | M | Option (right to buy) | 10 | $0.00 | 82,490.0000 | 324,556,000 | 0.01% | 0.00% |
| Feb. 28, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | M | Option (right to buy) | 82490 | $0.00 | 0.0000 | 324,556,000 | 100.00% | 0.03% |
| Feb. 28, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | M | Common Stock | 82490 | $14.74 | 439,797.0000 | 324,556,000 | 23.09% | 0.03% |
| Feb. 15, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | F | Common Stock | 1529 | $18.08 | 357,307.0000 | 324,556,000 | 0.43% | 0.00% |
| Jan. 5, 2023 | EXELIXIS, INC. | $EXEL | Aftab Dana | CSO/EVP Disc & Trans Research | A | Common Stock | 100000 | $0.00 | 358,836.0000 | 324,556,000 | 38.63% | 0.03% |